-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Compilenewborn
Sanofi's amcenestrant breast cancer program has suffered a setback in recent days, failing a key clinical test
On March 14, Sanofi announced the results of the clinical trial (AMEERA-3) of amcenestrant as a monotherapy for second- or multi-line treatment of ER+/HER2- advanced or metastatic breast cancer
AMEERA-3 is an open-label phase 2 trial evaluating amcenestrant, an oral selective estrogen receptor degrader, in 367 patients with ER+/HER2- locally advanced or metastatic breast cancer who had previously received hormone therapy.
Currently, Sanofi is continuing to advance two other amcenestrant trials
Results of the AMEERA-3 trial were originally expected to be announced in the second quarter of 2021
Reference source: Sanofi Long wait for pivotal data on Sanofi's oral SERD ends in failure